291 related articles for article (PubMed ID: 23040422)
1. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial.
Simmons RK; Echouffo-Tcheugui JB; Sharp SJ; Sargeant LA; Williams KM; Prevost AT; Kinmonth AL; Wareham NJ; Griffin SJ
Lancet; 2012 Nov; 380(9855):1741-8. PubMed ID: 23040422
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial.
Griffin SJ; Rutten GEHM; Khunti K; Witte DR; Lauritzen T; Sharp SJ; Dalsgaard EM; Davies MJ; Irving GJ; Vos RC; Webb DR; Wareham NJ; Sandbæk A
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):925-937. PubMed ID: 31748169
[TBL] [Abstract][Full Text] [Related]
3. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial.
Griffin SJ; Borch-Johnsen K; Davies MJ; Khunti K; Rutten GE; Sandbæk A; Sharp SJ; Simmons RK; van den Donk M; Wareham NJ; Lauritzen T
Lancet; 2011 Jul; 378(9786):156-67. PubMed ID: 21705063
[TBL] [Abstract][Full Text] [Related]
4. The ADDITION-Cambridge trial protocol: a cluster -- randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients.
Echouffo-Tcheugui JB; Simmons RK; Williams KM; Barling RS; Prevost AT; Kinmonth AL; Wareham NJ; Griffin SJ
BMC Public Health; 2009 May; 9():136. PubMed ID: 19435491
[TBL] [Abstract][Full Text] [Related]
5. Effect of population screening for type 2 diabetes and cardiovascular risk factors on mortality rate and cardiovascular events: a controlled trial among 1,912,392 Danish adults.
Simmons RK; Griffin SJ; Witte DR; Borch-Johnsen K; Lauritzen T; Sandbæk A
Diabetologia; 2017 Nov; 60(11):2183-2191. PubMed ID: 28831535
[TBL] [Abstract][Full Text] [Related]
6. HbA1c and cardiovascular risk score identify people who may benefit from preventive interventions: a 7 year follow-up of a high-risk screening programme for diabetes in primary care (ADDITION), Denmark.
Lauritzen T; Sandbaek A; Skriver MV; Borch-Johnsen K
Diabetologia; 2011 Jun; 54(6):1318-26. PubMed ID: 21340624
[TBL] [Abstract][Full Text] [Related]
7. Does training of general practitioners for intensive treatment of people with screen-detected diabetes have a spillover effect on mortality and cardiovascular morbidity in 'at risk' individuals with normoglycaemia? Results from the ADDITION-Denmark cluster-randomised controlled trial.
Simmons RK; Bruun NH; Witte DR; Borch-Johnsen K; Jørgensen ME; Sandbæk A; Lauritzen T
Diabetologia; 2017 Jun; 60(6):1016-1021. PubMed ID: 28280901
[TBL] [Abstract][Full Text] [Related]
8. Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: a controlled trial among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009.
Simmons RK; Griffin SJ; Lauritzen T; Sandbæk A
Diabetologia; 2017 Nov; 60(11):2192-2199. PubMed ID: 28831539
[TBL] [Abstract][Full Text] [Related]
9. Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening.
Webb DR; Khunti K; Srinivasan B; Gray LJ; Taub N; Campbell S; Barnett J; Henson J; Hiles S; Farooqi A; Griffin SJ; Wareham NJ; Davies MJ
Trials; 2010 Feb; 11():16. PubMed ID: 20170482
[TBL] [Abstract][Full Text] [Related]
10. HbA1c as predictor of all-cause mortality in individuals at high risk of diabetes with normal glucose tolerance, identified by screening: a follow-up study of the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION), Denmark.
Skriver MV; Borch-Johnsen K; Lauritzen T; Sandbaek A
Diabetologia; 2010 Nov; 53(11):2328-33. PubMed ID: 20697688
[TBL] [Abstract][Full Text] [Related]
11. Pharmacy Diabetes Screening Trial: protocol for a pragmatic cluster-randomised controlled trial to compare three screening methods for undiagnosed type 2 diabetes in Australian community pharmacy.
Krass I; Carter R; Mitchell B; Mohebbi M; Shih STF; Trinder P; Versace VL; Wilson F; Namara KM
BMJ Open; 2017 Dec; 7(12):e017725. PubMed ID: 29284715
[TBL] [Abstract][Full Text] [Related]
12. Screening for type 2 diabetes: a short report for the National Screening Committee.
Waugh NR; Shyangdan D; Taylor-Phillips S; Suri G; Hall B
Health Technol Assess; 2013 Aug; 17(35):1-90. PubMed ID: 23972041
[TBL] [Abstract][Full Text] [Related]
13. Let's prevent diabetes: study protocol for a cluster randomised controlled trial of an educational intervention in a multi-ethnic UK population with screen detected impaired glucose regulation.
Gray LJ; Khunti K; Williams S; Goldby S; Troughton J; Yates T; Gray A; Davies MJ;
Cardiovasc Diabetol; 2012 May; 11():56. PubMed ID: 22607160
[TBL] [Abstract][Full Text] [Related]
14. Effect of early intensive multifactorial therapy compared with routine care on self-reported health status, general well-being, diabetes-specific quality of life and treatment satisfaction in screen-detected type 2 diabetes mellitus patients (ADDITION-Europe): a cluster-randomised trial.
Van den Donk M; Griffin SJ; Stellato RK; Simmons RK; Sandbæk A; Lauritzen T; Khunti K; Davies MJ; Borch-Johnsen K; Wareham NJ; Rutten GE
Diabetologia; 2013 Aug; 56(11):2367-77. PubMed ID: 23959571
[TBL] [Abstract][Full Text] [Related]
15. Screening for type 2 diabetes. Lessons from the ADDITION-Europe study.
van den Donk M; Sandbaek A; Borch-Johnsen K; Lauritzen T; Simmons RK; Wareham NJ; Griffin SJ; Davies MJ; Khunti K; Rutten GE
Diabet Med; 2011 Nov; 28(11):1416-24. PubMed ID: 21679235
[TBL] [Abstract][Full Text] [Related]
16. Record-based, stepwise screening for type 2 diabetes integrated into an annual cardiovascular care review system: Findings from a UK general practice.
Fisher BG; Ang YL; Goodhart C; Simmons RK
Prim Care Diabetes; 2011 Dec; 5(4):265-9. PubMed ID: 21968319
[TBL] [Abstract][Full Text] [Related]
17. Screening for type 2 diabetes: literature review and economic modelling.
Waugh N; Scotland G; McNamee P; Gillett M; Brennan A; Goyder E; Williams R; John A
Health Technol Assess; 2007 May; 11(17):iii-iv, ix-xi, 1-125. PubMed ID: 17462167
[TBL] [Abstract][Full Text] [Related]
18. Who attends a UK diabetes screening programme? Findings from the ADDITION-Cambridge study.
Sargeant LA; Simmons RK; Barling RS; Butler R; Williams KM; Prevost AT; Kinmonth AL; Wareham NJ; Griffin SJ
Diabet Med; 2010 Sep; 27(9):995-1003. PubMed ID: 20722672
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study.
Li G; Zhang P; Wang J; An Y; Gong Q; Gregg EW; Yang W; Zhang B; Shuai Y; Hong J; Engelgau MM; Li H; Roglic G; Hu Y; Bennett PH
Lancet Diabetes Endocrinol; 2014 Jun; 2(6):474-80. PubMed ID: 24731674
[TBL] [Abstract][Full Text] [Related]
20. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study.
Currie CJ; Peters JR; Tynan A; Evans M; Heine RJ; Bracco OL; Zagar T; Poole CD
Lancet; 2010 Feb; 375(9713):481-9. PubMed ID: 20110121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
